



## Gene Delivery and Gene Editing

Guest Editor:

### Dr. Kosuke Ishikawa

Japan Biological Informatics  
Consortium (JBIC), 2-4-32 Aomi,  
Koto-ku, Tokyo 135-8073, Japan

Deadline for manuscript  
submissions:

**31 August 2024**

### Message from the Guest Editor

While gene delivery and editing technologies have become commonplace due to the prevalence of highly advanced methods, it is essential to recognize that ongoing development is imperative. The ultimate role of genetic engineers is to acquire a flawless technology that can, in a specific and efficient manner, revert mutated or defective genes to their healthy wild-type form without any side effects.

In this Special Issue, we aim to compile reviews addressing the current status, challenges, and issues related to gene editing, gene delivery technologies, and peripheral technologies in drug development, diagnostics, and medicine. We also expect comprehensive articles that present new insights from diverse perspectives. We are particularly interested in exploring the potential of new functional modules for CRISPR-Cas, proteins beyond typical Cas proteins, advancements in TALEN, the discovery and characterization of unknown type I or II transposons and viruses, and the medical applications stemming from these discoveries.

- gene delivery
- gene editing
- novel module
- transposon
- genetic engineering





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](https://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](https://twitter.com/Biomed_MDPI)